Alba Valiente-Pallejà

Alba Valiente-Pallejà

Auto-generated profile, based on publicly available information

Alba Valiente-Pallejà

Hospital Universitari Institut Pere Mata (HUIPM) Reus Catalonia Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Schizophrenia Research
Verified
Journal Article
Closed access
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
Helena TorrellHelena Torrell
Helena Torrell
YFYolanda Alonso Fernández
Yolanda Alonso Fernández
EVElisabet Vilella
Elisabet Vilella
GMGerard Muntane
Gerard Muntane
Lourdes MartorellLourdes Martorell
Lourdes Martorell

24 April 2020 in Acta Neuropsychiatrica
Verified
Journal Article
Closed access
PDF file
YAYolanda Alonso
Yolanda Alonso
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
BVBegoña Verge
Begoña Verge
EVElisabet Vilella
Elisabet Vilella
Lourdes MartorellLourdes Martorell
Lourdes Martorell
Objective: It has been hypothesised that neuropsychiatric symptoms, including psychosis, can be the result of a milder brain bioenergetic defect produced by mitochondrial dysfunction; however, mitochondrial dysfunction can be present in other organs or systems. The aim of the study was to investigate whether clinical conditions associated with mitochondrial disorders (CAMDs) were frequently present in schizophrenia.Methods: A previously used questionnaire regarding the CAMDs was administered to patients and controls in a direct interview with a trained psychiatrist. The frequencies of CAMDs in 164 patients with schizophrenia were compared to those in 156 age- and sex-matched controls.Results: Severe fatigue, seizures, constipation and diabetes were significantly more frequent in patients with schizophrenia than in control subjects and apparently not related to pharmacological treatment.Conclusion: The results of the present study suggest that multi-systemic mitochondrial dysfunction may be an underlying mechanism involved in schizophrenia.

1 October 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
JVJuan Tortajada Valero
Juan Tortajada Valero
BBBengisu Bulduk
Bengisu Bulduk
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
EVElisabet Vilella
Elisabet Vilella
GMGerard Muntane
Gerard Muntane
Lourdes MartorellLourdes Martorell
Lourdes Martorell

27 September 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
BBBengisu Bulduk
Bengisu Bulduk
LTLeire Torres-Egurrola
Leire Torres-Egurrola
JVJuan Tortajada Valero
Juan Tortajada Valero
AVAlba Valiente-Pallejà
Alba Valiente-Pallejà
Helena TorrellHelena Torrell
Helena Torrell
GMGerard Muntane
Gerard Muntane

1 June 2026 in General Psychiatry
Verified
Journal Article
Open access
JTJuan Tortajada
Juan Tortajada
BBBengisu Kevser Bulduk
Bengisu Kevser Bulduk
BABelén Alfonso‐Landete
Belén Alfonso‐Landete
PAPaula Alcaide‐Barriga
Paula Alcaide‐Barriga
BBBernat Ballvé‐Gelonch
Bernat Ballvé‐Gelonch
Lourdes MartorellLourdes Martorell
Lourdes Martorell
Background: Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims: To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, we searched PubMed, Embase and Scopus databases from 1 January 2007 to 30 April 2024. Reports were included if they evaluated outcomes of nutraceutical supplementation in patients with psychiatric disorders or related conditions. Additionally, we performed a risk‐of‐bias analysis of the studies compatible with the RoB2 tool. Results: Of the 2061 records identified, 122 studies met the inclusion criteria, evaluating vitamin D3, N‐acetylcysteine, acetyl‐L‐carnitine, coenzyme Q10, alpha‐lipoic acid, magnesium, vitamin B6, vitamin B7, folic acid, vitamin B12, vitamin E, vitamin A, vitamin C and vitamin B3. The most studied nutraceuticals were vitamin D3 (27.05%) and N‐acetylcysteine (15.6%). Among randomised controlled clinical trials (RCTs), vitamin D3 was the most extensively investigated and accounted for the highest number of trials reporting improvements in clinical outcomes, although findings were heterogeneous. Notably, 14.8% of the studies evaluated combinations of three or more nutraceuticals. Dietary supplements were extensively evaluated for autism spectrum disorder (28 studies), schizophrenia spectrum disorder (27 studies), major depressive disorder or related depressive symptoms (22 studies), attention‐deficit hyperactivity disorder (9 studies) and bipolar spectrum disorder (6 studies). A substantial proportion of studies were not RCTs but open‐label single‐arm trials or case reports. Significant heterogeneity was observed in the nutraceutical components used, treatment duration and the outcomes assessed. Overall, the risk of bias was high, and the methodological quality was generally low. Conclusions: Promising findings in nutraceutical studies for psychiatric disorders face challenges, including small sample sizes, short follow‐up periods and a lack of treatment standardisation. Future research requires robust RCTs with standardised protocols and validated biomarkers of efficacy.